CDKN2A and melanoma: In contrast, substantial loss or complete absence of p16 expression is frequently encountered in malignant melanoma, where it represents a surrogate marker of CDKN2A inactivation, typically due to homozygous deletion, mutation, or promoter hypermethylation.